Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW
Peter Rossing, Morten Lindhardt, Christian Klyver Tikkanen, Jyothi Menon, Juliette Cattin, Barnaby Hunt, Samuel J. P. Malkin, Barrie Chubb, Tina Damgaard, Rikke Borg · 2025
Read Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW by Peter Rossing, Morten Lindhardt, Christian Klyver Tikkanen, Jyothi Menon, Juliette Cattin, Barnaby Hunt, Samuel J. P. Malkin, Barrie Chubb, Tina Damgaard, Rikke Borg (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12862915.txt.
Description
Peter Rossing and co-authors present a 2025 cost study for Denmark on once-weekly semaglutide in people who have both type 2 diabetes and chronic kidney disease. The work builds on the FLOW trial, which found that the drug protected kidneys and the heart when added to standard care. The authors ask whether those gains are worth the cost over a lifetime.
A diabetes model projected life span, quality-adjusted life years, complications, and costs for the drug versus placebo. Inputs came from FLOW, with Danish costs and quality-of-life values added. The drug was projected to add 0.60 quality-adjusted life years in the full group. Gains held in subgroups split by use of a second drug class at the start.
Catalog record
| CREATOR | Peter Rossing, Morten Lindhardt, Christian Klyver Tikkanen, Jyothi Menon, Juliette Cattin, Barnaby Hunt, Samuel J. P. Malkin, Barrie Chubb, Tina Damgaard, Rikke Borg |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 68 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |